BridgeBio Pharma Inc. has announced the full enrollment of 71 participants in its Phase 3 clinical trial, CALIBRATE, which is evaluating encaleret for the treatment of autosomal dominant hypocalcemia type 1 (ADH1). This trial is the largest prospective interventional study ever conducted for ADH1. BridgeBio expects to report topline results in the second half of 2025. If successful, encaleret could become the first approved therapy for individuals with ADH1. Additionally, the company plans to initiate a registrational study of encaleret in chronic hypoparathyroidism in 2026. This follows the publication of an analysis in the American Journal of Human Genetics, which confirmed prior estimates of the genetic prevalence of ADH1 and highlighted the underdiagnosis of the condition.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.